Unknown

Dataset Information

0

Bladder cancer detection by urinary extracellular vesicle mRNA analysis.


ABSTRACT:

Objective

Urinary extracellular vesicles (EV) could be promising biomarkers for urological diseases. In this retrospective feasibility study, we conducted biomarker screening for early stage bladder cancer using EV mRNA analysis.

Methods

Biomarker candidates were identified through RNA-seq analysis of urinary EV from patients with non-muscle invasive bladder cancer (N=3), advanced urothelial cancer (N=3), no residual tumor after TURBT (N=2), and healthy and disease controls (N=4). Diagnostic performance was evaluated by RT-qPCR in a larger patient group including bladder cancer (N=173), renal pelvis and ureter cancer (N=33), no residual tumor and non-cancer disease control (N=36).

Results

Urinary EV SLC2A1, GPRC5A and KRT17 were overexpressed in pT1 and higher stage bladder cancer by 20.6-fold, 18.2-fold and 29.5-fold, respectively. These genes allowed detection of non-muscle invasive bladder cancer (AUC: 0.56 to 0.64 for pTa, 0.62 to 0.80 for pTis, and 0.82 to 0.86 for pT1) as well as pT2 and higher muscle invasive bladder cancer (AUC: 0.72 to 0.90). Subgroup analysis indicated that these markers could be useful for the detection of cytology-negative/-suspicious and recurrent bladder cancers.

Conclusion

Three urinary EV mRNA were discovered to be elevated in bladder cancer. Urinary EV mRNA are promising biomarkers of urothelial cancer and worth further investigation.

SUBMITTER: Murakami T 

PROVIDER: S-EPMC6132352 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Objective</h4>Urinary extracellular vesicles (EV) could be promising biomarkers for urological diseases. In this retrospective feasibility study, we conducted biomarker screening for early stage bladder cancer using EV mRNA analysis.<h4>Methods</h4>Biomarker candidates were identified through RNA-seq analysis of urinary EV from patients with non-muscle invasive bladder cancer (N=3), advanced urothelial cancer (N=3), no residual tumor after TURBT (N=2), and healthy and disease controls (N=4).  ...[more]

Similar Datasets

| S-EPMC5710916 | biostudies-literature
2022-02-05 | GSE196156 | GEO
2023-11-27 | GSE218929 | GEO
| S-EPMC8343017 | biostudies-literature
| S-EPMC8088963 | biostudies-literature
| S-EPMC8620260 | biostudies-literature
2019-11-29 | E-MTAB-7123 | biostudies-arrayexpress
| S-EPMC8485336 | biostudies-literature
| S-EPMC7881020 | biostudies-literature
| S-EPMC5029630 | biostudies-literature